Inovio Pharmaceuticals Inc stock is traded at $1.62, with a volume of 21,003,379. It is down -2.41% in the last 24 hours and up +39.66% over the past month. Inovio Pharmaceuticals Inc is a clinical-stage biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from diseases associated with human papillomavirus (HPV), cancer and infectious diseases. INOVIO's platform harnesses the power of in vivo protein production, featuring optimized design and delivery of DNA medicines that teach the body to manufacture its own disease-fighting tools. Its candidate is INO-3107 for the treatment of recurrent respiratory papillomatosis (RRP), a chronic, rare and debilitating disease of the respiratory tract caused by HPV infection. In its completed Phase 1/2 clinical trial of INO-3107 for the treatment of HPV-6 and HPV-11-associated RRP.
Previous Close:
$1.66
Open:
$1.67
24h Volume:
21,003,379
Relative Volume:
0.53
Market Cap:
$167.50M
Revenue:
$65,300
Net Income/Loss:
-$84.93M
P/E Ratio:
-
EPS:
-$1.71
Net Cash Flow:
-$83.57M
1W Performance:
+74.46%
1M Performance:
+39.66%
6M Performance:
+42.11%
1Y Performance:
-33.33%
1-Day Range:
$1.55$1.85
1-Week Range:
$0.5961$2.17
52-Week Range:
$0.5632$2.72
Inovio Pharmaceuticals Inc Stock (INO) Company Profile
Name
Inovio Pharmaceuticals IncSector
HealthcareIndustry
BiotechnologyPhone
(858) 410-3134Address
660 W. GERMANTOWN PIKE, PLYMOUTH MEETING, PA, USAMarket Cap
Revenue
Net Income
Cash Flow
EPS